Suppliers / Reliance Life Sciences

Reliance Life Sciences

India reconciled across 6 public records · 2 entities Updated 9 July 2026

Reliance Life Sciences is an API and finished-dose manufacturer based in India. It holds 13 active US drug master files across a filed portfolio of 15 molecules. Its filings concentrate with DIGEMAPS (DO), INHRR (VE) and ARCSA (EC). Its GMP standing is certified by EMA, ANVISA (Brazil) and EAEU_EEC, among 6 authorities. Its most recent recorded inspection, by US FDA, closed on 15 April 2022 as NAI. Customs aggregates show $6.3M of exports covering 107 molecules to 21 destinations in 2025.

13
active US DMFs
0
valid CEPs
9
registered plants 1 with an FDA FEI number
162
filings across 13 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
7 of 7 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 15 April 2022 NAI US FDA
  • 22 November 2019 VAI US FDA
  • 16 October 2018 VAI US FDA
  • 25 January 2018 NAI US FDA
  • 13 December 2017 VAI US FDA
  • 14 August 2015 VAI US FDA
  • 23 August 2013 OAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Navi Mumbai, United Arab Emirates Not on file
Maharashtra, United Arab Emirates Not on file
Mumbai 24239 Mh 2011 Ptc 130654, Colombia Not on file
Maharashtra, Colombia Not on file
NAVI MUMBAI, India Not on file
NAVI MUMBAI (NOVA BOMBAIM), India Not on file

3 further sites are on record.

What they file, and where

Molecule Regulators Docs
Bortezomib SFDA (Saudi Arabia), US FDA 3
Erlotinib SFDA (Saudi Arabia), US FDA 3
Lenalidomide SFDA (Saudi Arabia), US FDA 3
Pemetrexed SFDA (Saudi Arabia), US FDA 3
Azacitidine US FDA 2
Capecitabine US FDA 2
Dasatinib US FDA 2
Decitabine US FDA 2
Imatinib US FDA 2
Lanreotide US FDA 2
Show all 15 molecules on file
Sorafenib US FDA 2
Sunitinib US FDA 2
Temozolomide US FDA 2
Pemetrexed Disodium SFDA (Saudi Arabia) 1
Sunitinib Malate SFDA (Saudi Arabia) 1

Also appears on these molecule pages

Azacitidine API Bortezomib API Capecitabine API Dasatinib API Decitabine API Erlotinib API Histidine finished dose Imatinib API Lanreotide API Lenalidomide API Pemetrexed API Pemetrexed Disodium API
Show 3 more molecule pages
Sorafenib API Sunitinib API Temozolomide API

Filings and GMP by regulator

Regulator Filings GMP certificates
DIGEMAPS (DO) 54 None
INHRR (VE) 32 None
ARCSA (EC) 23 None
CDSCO (India) 18 None
MINSA (CR) 6 None
EDE (AE) 6 None
EMA None 10
ANVISA (Brazil) None 3
EAEU_EEC None 3
INVIMA (CO) None 2
UZPHARM (UZ) None 2
MHRA (UK) None 1

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $23.9M 41
2025 Not reported $6.3M 21

Export figures are customs aggregates. We do not publish the identity of any buyer.

Questions about Reliance Life Sciences

Does Reliance Life Sciences hold a US DMF or a CEP?
Reliance Life Sciences holds 13 active US drug master files. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Reliance Life Sciences FDA-registered?
One site operated by Reliance Life Sciences carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Reliance Life Sciences's last inspection go?
The most recent inspection on record closed on 15 April 2022 as NAI (No Action Indicated: nothing objectionable was found). 7 inspections are on file, of which 1 closed as OAI.
Where does Reliance Life Sciences manufacture?
9 registered sites are on record, in United Arab Emirates, Colombia and India (Navi Mumbai, Maharashtra and Mumbai 24239 Mh 2011 Ptc 130654 among others). Every site is listed on this page with the register it came from.
What does Reliance Life Sciences make?
15 molecules are on record against Reliance Life Sciences, including Bortezomib, Erlotinib, Lenalidomide and Pemetrexed. Each links through to that molecule's full manufacturer list.
Which regulators recognise Reliance Life Sciences's GMP?
Current GMP certificates are on record from EMA, ANVISA (Brazil), EEC (Eurasian Economic Union), INVIMA (CO), UZPHARM (UZ) and 1 more. GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Reliance Life Sciences comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 15 April 2022.

Comparable suppliers

MSN Laboratories shares 12 molecules Hetero shares 12 molecules Shilpa Pharma Lifesciences shares 12 molecules Dr Reddy's Laboratories shares 10 molecules Laurus Labs shares 7 molecules

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts